[
    [
        {
            "time": "",
            "original_text": "COVID-19研发动态：Vir/Alnylam确定候选RNA疗法；和铂医药，君实生物中和抗体开发获得进展",
            "features": {
                "keywords": [
                    "COVID-19",
                    "RNA疗法",
                    "和铂医药",
                    "君实生物",
                    "中和抗体"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "COVID-19研发动态：Vir/Alnylam确定候选RNA疗法；和铂医药，君实生物中和抗体开发获得进展",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]